<DOC>
	<DOCNO>NCT02160262</DOCNO>
	<brief_summary>To evaluate long-term safety tolerability SEP 225289 adult subject Attention Deficit Hyperactivity Disorder ( ADHD )</brief_summary>
	<brief_title>Open-label Safety Study Adults With ADHD</brief_title>
	<detailed_description>To evaluate long-term safety tolerability SEP 225289 adult subject ADHD incidence adverse event ( AEs ; serious AEs ) , AEs ( SAEs ) lead discontinuation</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject meet DSM 5 criterion primary diagnosis ADHD ( inattentive , hyperactive , combined presentation ) establish comprehensive psychiatric evaluation review DSM 5 criterion . Diagnosis confirm CAADID Part 2 checklist DSM 5 . Subject ADHD RS IV adult prompt score ≥ 22 screen baseline . Subject agree participate providing write informed consent willing able comply protocol , opinion investigator . Subject 18 55 year old , inclusive , time informed consent . Subject male nonpregnant , non lactate female . Female subject must negative serum pregnancy test ; females post menopausal ( define least 12 month spontaneous amenorrhea ) undergone hysterectomy bilateral oophorectomy exempt pregnancy test . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control throughout study period . Subject negative breath alcohol test negative urine drug screen ( UDS ) illicit drug screening . Subject judge investigator suitable participation 12 month clinical trial involve openlabel dasotraline treatment . Subject read well enough understand informed consent form subject material . Subject psychiatric disorder ADHD primary focus treatment time 12 month prior screen . Subject past history , current presentation consistent , bipolar disorder ( include bipolar I bipolar II ) , schizophrenia , schizoaffective disorder , psychotic disorder , personality disorder per DSM 5 criterion . Subject history substance abuse drug dependence ( exclude nicotine caffeine ) within 12 month prior screen , define DSM 5 criterion . Subject history epilepsy , seizure ( except childhood febrile seizure ) , unexplained syncope unexplained blackout ( except single incident ) , head trauma loss consciousness last 5 minute . Subject currently active medical condition ( ADHD ) , opinion investigator , could interfere ability subject participate study . Subject currently take take within previous 6 month anticonvulsant medication ( eg , phenytoin , carbamazepine , lamotrigine , valproic acid , etc ) ; antipsychotic medication ; lithium ( lithium preparation formulation ) . Subject currently take alpha 2 adrenergic receptor agonist ( include clonidine guanfacine ) , serotoninnorepinephrine reuptake inhibitor ( SNRI ; eg , venlafaxine ) , dopaminenorepinephrine reuptake inhibitor ( DNRI ; eg , bupropion ) , monoamine oxidase [ MAO ] inhibitor . Note : Subjects discontinue medication washout minimum 7 day prior first dose study drug allow enroll study . Subject currently undergo Cognitive Behavioral Therapy ( CBT ) . Subject Body Mass Index ( BMI ) less 18 great 35 kg/m2 ( see Appendix V ) . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) C SSRS assessment screening ( past month ) . Subjects answer `` yes '' question must refer investigator follow evaluation . Subject attempt suicide within 1 year prior screening period . Subject history positive test Hepatitis B surface antigen Hepatitis C antibody liver function test result screen upper limit normal reference lab . Subject know tested positive human immunodeficiency virus ( HIV ) . Subject clinically significant abnormality screen evaluation include physical examination , vital sign , ECG , laboratory test investigator considers inappropriate allow participation study . The subject 's screening ECG show correct QT interval use Fridericia 's formula ( QTcF ) ≥ 450 msec male subject ≥ 470 msec female subject . Eligibility base core laboratory ECG interpretation report . The subject 's screening serum chemistry result show alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value ≥ 2 time upper limit normal ( ULN ) , blood urea nitrogen ( BUN ) value ≥ 1.5 time ULN reference laboratory . Subject currently participate participate clinical trial within last 90 day participate 2 clinical trial within past year . This include study use marketed compound device . Subject history allergic reaction know suspected sensitivity substance contain study drug formulation . Subject previously randomize clinical trial dasotraline . Subject likely noncompliant investigator 's opinion . Subject investigational site staff member relative investigational site staff member .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>